Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00964093 · ClinicalTrials.gov registry record · NA
The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants
A NA study of Central Line Bloodstream Infections, sponsored by Baylor Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00964093 is a NA study of Central Line Bloodstream Infections that has completed, run by Baylor Research Institute. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00964093, a NA study of Central Line Bloodstream Infections, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether silver alginate (Algidex) patch is effective in the prevention of central line infections in very low birth weight infants.
Conditions Studied
Interventions
- DEVICE Silver Alginate
Study Locations (1)
Texas
- Baylor University Medical Center - Women and Children's Services - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-11-23 |
| Est. Completion | 2015-08-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00964093
The ClinicalTrials.gov registry entry for NCT00964093 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Line Bloodstream Infections appearing as the primary indexed condition, and to 1 intervention - of which Silver Alginate is the first listed.
NCT00964093 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00964093 about?
NCT00964093 is a clinical study titled "The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants". The purpose of this study is to determine whether silver alginate (Algidex) patch is effective in the prevention of central line infections in very low birth weight infants.
What is the current status of trial NCT00964093?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2008-11-23. Estimated completion is 2015-08-20.
What conditions does trial NCT00964093 study?
This clinical trial studies the following conditions: Central Line Bloodstream Infections.
What interventions are being tested in trial NCT00964093?
The interventions under investigation include: Silver Alginate (DEVICE).
Who is sponsoring clinical trial NCT00964093?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00964093 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.